Avrok Biosciences

What If Your Diagnosis Had No Treatment? For 1 in 10 Americans with a rare disease, this is their reality. ?? 10,000+ #rarediseases exist—but fewer than 5% have an FDA-approved treatment. ?? 15 million children in the U.S. are affected, with 30% not surviving past age 5. Behind these statistics are real people, real families, real challenges. Let’s work toward better research, better care, and better futures for those living with rare diseases. National Organization for Rare Disorders Avrok Biosciences #RareDiseaseDay #RareDiseaseWeek #NORD

For 95% of rare diseases, treatment options don’t exist. With small patient populations and complex research challenges, #drugdevelopment is an uphill battle. During this #RareDiseaseWeek, Avrok Biosciences recognizes the need for continued research, stronger advocacy, and better access to care for those affected. Let’s push for change and support those who need it most. ?? #OrphanDrugs #Advocacy #PrecisionMedicine?

Behind every cancer statistic is a real person, a family, and a community seeking hope and breakthroughs. #NationalCancerPreventionMonth is a global call to action—reminding us that through research, collaboration, and innovation, we can drive progress against this disease. Science is advancing faster than ever. Avrok Biosciences is committed to providing researchers with high-quality samples and state-of-the-art processing capabilities to fuel discoveries in cancer diagnostics and treatment. This month, we stand with patients, scientists, and advocates in the fight against cancer. Together, we are transforming research into real solutions. #TranslationalScience #BiospecimensMatter #CancerResearch

Not every project requires high-resolution HLA typing. Avrok Biosciences’ low-resolution #HLATyping offers a reliable, cost-effective alternative for preliminary studies and quick insights. Low-resolution HLA typing identifies broader gene groups within the human leukocyte antigen (HLA) system, making it ideal for applications that don’t require ultra-detailed data but still demand accuracy. Here’s how it can benefit you: - Preliminary Donor Screening: Efficiently screen large pools with accurate foundational data. - Epidemiology & Population Studies: Map HLA diversity without detailed allelic resolution. - Budget-Friendly Research: Reduce costs without sacrificing essential data. ?? Ready to learn more? Contact Avrok to see how we can support your goals. ? https://lnkd.in/eYVxzvNA #Genomics #LifeSciences #PrecisionMedicine

#SuperBowlSunday is almost here. Will your team bring home the trophy, or are you just here for the commercials? Cast your vote! ????? #KansasCityChiefs #PhiladelphiaEagles #SuperBowlLIX

Every breakthrough starts with research—and action. Behind every lifesaving treatment is a team of researchers working to detect, diagnose, and treat cancer earlier. But #WorldCancerDay is more than just a day—it’s a call to action for all of us. Whether you’re a #researcher, advocate, or patient, we each play a role in advancing early detection, improving access to care, and closing the #cancer care gap. Together, we can make cancer a preventable and treatable disease. Read more in Avrok Biosciences latest blog post: World Cancer Day 2025: The Power of Early Detection in the Fight Against Cancer #cancerresearch #biotech

Efficient biospecimen processing can make or break a study. How do you handle #biospecimen processing in your workflow? Let us know how you manage your samples. #LifeSciences #LabOperations #TranslationalResearch #Biobanking

Here is a little #lab humor to get you through the week! ???? Which one do you relate to the most? #LabLife #ScienceHumor

#NationalBloodDonorMonth reminds us of the vital role blood donations play in saving lives and supporting medical care. Beyond the clinic, #blood donations are essential for driving #biomarker discovery and developing innovative therapies, fueling groundbreaking advancements in #biopharma research. Avrok Biosciences provides biopharma #researchers with access to non-invasive biospecimen collection (including blood!) for their research. Read more in our latest blog post. American Red Cross #biotech #pharma

Outbreak readiness starts with smarter screening. Whether individual testing or population monitoring, the PAN25+ Screening Panel from Avrok Biosciences a streamlined, accurate solution to detect and track emerging #pathogens like #H5N1 and SARS-CoV-2. This advanced platform screens for over 25 respiratory viruses and offers?precise strain differentiation, critical for combating emerging #viral threats. Discover why PAN25+ is essential for today’s challenges. #AvianFlu #InfectiousDisease